Research.Patient.info
Relapsed or Refractory Chronic Lymphocytic Leukemia research hub
2 indexed studies · 1 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
A Multi-Center, Open Label, Uncontrolled, Phase 2a Clinical Trial Evaluating the Safety and Efficacy of the Addition of Ibrutinib to Venetoclax through a MRD-guided Approach in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia (CLL) IMPROVE (Ibrutinib treatment based on MRD-guided apPROach combined with VEnetoclax)
This study looks at a new way to treat chronic lymphocytic leukaemia (CLL) that has returned or stopped responding to treatment. Doctors are testing whether combining two targeted medicines, venetoclax and ibrutinib, based on sensitive blood tests that look for hidden leukaemia cells, can clear the cancer more effectively.
Italy - active not recruitingPHASE2
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction
This study looks at combining two drugs, ibrutinib and daratumumab, for people with chronic lymphocytic leukemia (CLL) that has come back or not responded well to past treatments. It focuses on patients whose cancer has specific genetic changes, aiming to see if this combination works better.
France